Floatz logo

Icaritin

Advanced HBV-Related Hepatocellular Carcinoma (HCC)

Beijing Shenogen Biomedical Co., LtdSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

521 Active assets in the Advanced HBV-Related Hepatocellular Carcinoma (HCC) cohort.

Asset / SponsorPhaseRating
Huaier Granule
Tongji Hospital
Phase 4BBB
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Theprubicin
RWTH Aachen University
Phase 4BB
Carboplatin
AstraZeneca
Phase 4BB

View all 50 →

Same molecule, other indications

Icaritin is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
63 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
54 / 100
View asset →
RFSDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →